Alnylam Pharmaceuticals Inc (ALNY) - Total Liabilities
Based on the latest financial reports, Alnylam Pharmaceuticals Inc (ALNY) has total liabilities worth $4.18 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ALNY shareholders equity momentum to track the company's year-over-year net asset growth rate.
Alnylam Pharmaceuticals Inc - Total Liabilities Trend (2002–2025)
This chart illustrates how Alnylam Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Alnylam Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Alnylam Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Commerzbank AG
XETRA:CBK
|
Germany | €571.14 Billion |
|
Garmin Ltd
F:GEY
|
Germany | €1.68 Billion |
|
Prudential plc
MX:PUKN
|
Mexico | MX$190.84 Billion |
|
Nokia Corp ADR
NYSE:NOK
|
USA | $16.53 Billion |
|
Bloom Energy Corp
NYSE:BE
|
USA | $3.60 Billion |
|
Consolidated Edison Inc
NYSE:ED
|
USA | $49.15 Billion |
|
Danone SA
F:BSND
|
Germany | €28.10 Billion |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-A
|
Sweden | Skr3.44 Trillion |
Liability Composition Analysis (2002–2025)
This chart breaks down Alnylam Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALNY company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alnylam Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alnylam Pharmaceuticals Inc (2002–2025)
The table below shows the annual total liabilities of Alnylam Pharmaceuticals Inc from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.18 Billion | +0.10% |
| 2024-12-31 | $4.17 Billion | +3.02% |
| 2023-12-31 | $4.05 Billion | +9.34% |
| 2022-12-31 | $3.70 Billion | +21.26% |
| 2021-12-31 | $3.06 Billion | +27.78% |
| 2020-12-31 | $2.39 Billion | +149.97% |
| 2019-12-31 | $956.44 Million | +250.55% |
| 2018-12-31 | $272.84 Million | +19.51% |
| 2017-12-31 | $228.30 Million | -33.36% |
| 2016-12-31 | $342.59 Million | +181.28% |
| 2015-12-31 | $121.80 Million | -15.02% |
| 2014-12-31 | $143.33 Million | -4.56% |
| 2013-12-31 | $150.18 Million | -2.14% |
| 2012-12-31 | $153.47 Million | -6.38% |
| 2011-12-31 | $163.92 Million | -30.26% |
| 2010-12-31 | $235.03 Million | -22.54% |
| 2009-12-31 | $303.42 Million | -13.94% |
| 2008-12-31 | $352.55 Million | +19.66% |
| 2007-12-31 | $294.62 Million | +658.71% |
| 2006-12-31 | $38.83 Million | +6.19% |
| 2005-12-31 | $36.57 Million | +83.17% |
| 2004-12-31 | $19.96 Million | -67.74% |
| 2003-12-31 | $61.89 Million | +198.16% |
| 2002-12-31 | $20.76 Million | -- |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more